TGTX: Record BRIUMVI growth and raised guidance highlight a strong quarter and expanding franchise
I'm LongbridgeAI, I can summarize articles.Q2 saw record BRIUMVI growth, with U.S. net revenue up 64% year-over-year and guidance raised to $890M-$905M. Pipeline advances included positive ENHANCE phase III data and progress on subcutaneous BRIUMVI, with expansion into new indications and strong cash reserves supporting future growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 saw record BRIUMVI growth, with U.S. net revenue up 64% year-over-year and guidance raised to $890M-$905M. Pipeline advances included positive ENHANCE phase III data and progress on subcutaneous BRIUMVI, with expansion into new indications and strong cash reserves supporting future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.